CryoPort (CYRX) to Release Quarterly Earnings on Thursday

CryoPort (NASDAQ:CYRX) is expected to be releasing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect CryoPort to post earnings of ($0.20) per share and revenue of $48.1770 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 5:00 PM ET.

CryoPort (NASDAQ:CYRX) last issued its quarterly earnings data on Monday, May 4th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.03). CryoPort had a negative return on equity of 7.92% and a net margin of 41.57%.The firm had revenue of $47.80 million during the quarter, compared to the consensus estimate of $44.86 million. On average, analysts expect CryoPort to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CryoPort Stock Performance

CYRX stock opened at $15.49 on Tuesday. CryoPort has a fifty-two week low of $6.69 and a fifty-two week high of $16.89. The business’s 50-day moving average is $15.46 and its two-hundred day moving average is $11.81. The company has a market cap of $780.70 million, a price-to-earnings ratio of 11.47 and a beta of 1.89.

Insider Activity at CryoPort

In other news, Director Ramkumar Mandalam sold 23,214 shares of the firm’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $15.44, for a total value of $358,424.16. Following the transaction, the director owned 67,894 shares of the company’s stock, valued at $1,048,283.36. This trade represents a 25.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Edward J. Zecchini sold 33,600 shares of CryoPort stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $14.47, for a total value of $486,192.00. Following the transaction, the insider directly owned 109,719 shares in the company, valued at approximately $1,587,633.93. The trade was a 23.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 227,641 shares of company stock worth $3,622,515. Corporate insiders own 9.50% of the company’s stock.

Institutional Investors Weigh In On CryoPort

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Engineers Gate Manager LP bought a new stake in shares of CryoPort during the 4th quarter valued at $277,000. Martingale Asset Management L P boosted its holdings in CryoPort by 26.0% in the 4th quarter. Martingale Asset Management L P now owns 27,125 shares of the company’s stock worth $260,000 after buying an additional 5,605 shares during the period. LPL Financial LLC boosted its holdings in CryoPort by 6.6% in the 4th quarter. LPL Financial LLC now owns 23,306 shares of the company’s stock worth $224,000 after buying an additional 1,433 shares during the period. PharVision Advisers LLC increased its stake in CryoPort by 50.4% in the 3rd quarter. PharVision Advisers LLC now owns 16,498 shares of the company’s stock worth $156,000 after buying an additional 5,531 shares in the last quarter. Finally, Creative Planning increased its stake in CryoPort by 102.4% in the 3rd quarter. Creative Planning now owns 26,063 shares of the company’s stock worth $247,000 after buying an additional 13,183 shares in the last quarter. 92.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on CYRX. Weiss Ratings upgraded CryoPort from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, May 6th. BTIG Research increased their price objective on shares of CryoPort from $17.00 to $25.00 and gave the stock a “buy” rating in a research note on Friday, July 24th. Needham & Company LLC raised their price objective on shares of CryoPort from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Guggenheim boosted their target price on shares of CryoPort from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Tuesday, May 5th. Finally, Jefferies Financial Group set a $13.50 target price on shares of CryoPort in a report on Monday, June 8th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $16.38.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.